18
PROMOTING RESEARCH AND INNOVATION The impact of our journals - the European Journal of Cardio-Thoracic Surgery (EJCTS) and Interdisciplinary Cardiovascular and Thoracic Surgery (ICVTS) – has increased year on year in recognition of the high-quality peer reviewed content published by both publications. X
-670
UARY
JAN
2023
SN
| IS
2753
A CUL VA S I C O I I D C CAR HORA T E RY AND G SUR SUE
IS E 36
1 |
M
VOLU
RD NT E
ISC
IPL
IN
A RY
R
er Surg cic hora ion io -T rfus Card ar Pe for ion scul ciat ioca Asso of Card d pean ar ro Bo Eu the pean Euro nal of Jour the cial and Offi
y
EJCTS
ICVTS
The quality and influence of articles published in EJCTS throughout 2021 resulted in an impact factor score of 4.534, a 0.9 increase from the previous year. EJCTS attracts over one million article views each year. Highly cited articles included EACTS/ESC guidelines on myocardial revascularisation.
Improving outcomes for patients requires a multidisciplinary team effort which is why, in 2022, we took the decision to change the focus of ICVTS and publish highly innovative, interdisciplinary research in order to encourage greater collaboration across multidisciplinary teams in cardiac, thoracic and vascular surgery. The journal relaunched as Interdisciplinary CardioVascular and Thoracic Surgery in early 2023.
Over 2,290 submissions were received by EJCTS last year from over 60 countries worldwide. Geographic diversity is also reflected in the journal’s editorial board, with members from Europe as well as China, Japan and the USA. The editors in chiefs, supported by the EACTS publications team, strive for a diverse editorial team with a strong focus on improving the gender balance of our editorial boards.
The journal’s impact factor also rose last year, reaching 1.978, with highly cited articles such as ‘Aortic dissection reconsidered: type, entry site, malperfusion classification adding clarity and enabling outcome prediction’.
CRITICALLY APPRAISING CLINICAL TRIALS The 36th EACTS Annual Meeting was the place to be to find out more about the latest clinical trials. The outstanding quality of submissions in 2022 meant we ran two Late Breaking Clinical Trials sessions, reinforcing the EACTS Annual Meeting as a key event in the calendar for the cardiothoracic community. Delegates had the opportunity to assess and critically appraise the latest data from over 12 studies designed to further improve outcomes for patients. This included: • the results of CAST-HF, a potentially practice changing prospective randomised controlled trial exploring shockwave therapy in patients with ischemic cardiomyopathy. • and the preliminary first in human trials results of the Excimer Laser Assisted Non-Occlusive Anastomosis, a robotic device which aims to improve coronary artery bypass grafting.